loader
Please Wait
Applying Filters...

Seqens Seqens

X

Approved Drug Products containing 6800 listed in the FDA Orange Book. Original Data : FDA Website

Client Virtual Booth
Menu
Filters Filter
Cross PopUp
FILTER :

filter

01 ABBVIE (3)

filter

01 CAPSULE;ORAL (2)

02 SOLUTION;ORAL (1)

filter

01 DISCN (3)

filter

01 PARADIONE (3)

filter

01 No (3)

URL Supplier Web Content
CAPSULE; ORAL
300MG
1982-01-01
6800
PARADIONE
DISCN
No
Abbvie Company Banner

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
URL Supplier Web Content
SOLUTION; ORAL
300MG/ML
1982-01-01
6800
PARADIONE
DISCN
No
Abbvie Company Banner

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier
URL Supplier Web Content
CAPSULE; ORAL
150MG
1982-01-01
6800
PARADIONE
DISCN
No
Abbvie Company Banner

ICRI Spring Convention

Not Confirmed

envelop Contact Supplier

Looking for FDA Orange Book APPLICATION 6800

Looking for FDA Orange Book APPLICATION 6800 3

19

AbbVie Inc, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

One of their notable products is PARAMETHADIONE, with a corresponding application number 6800.

Regulatory Information DISCN

With a dosage strength 300MG

Dosage Form Route CAPSULE; ORAL

Reference Listed Drug No

Approved since 1982-01-01

18

AbbVie Inc, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

One of their notable products is PARAMETHADIONE, with a corresponding application number 6800.

Regulatory Information DISCN

With a dosage strength 300MG/ML

Dosage Form Route SOLUTION; ORAL

Reference Listed Drug No

Approved since 1982-01-01

17

AbbVie Inc, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

One of their notable products is PARAMETHADIONE, with a corresponding application number 6800.

Regulatory Information DISCN

With a dosage strength 150MG

Dosage Form Route CAPSULE; ORAL

Reference Listed Drug No

Approved since 1982-01-01

Post Enquiry
POST ENQUIRY